Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

ResMed (NYSE: RMD) + stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 results. The results, out after market close yesterday ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the second quarter of fiscal 2025 were $2.43, up 29.2% year over year. The metric beat the Zacks Consensus Estimate by 5.6%. The ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.

Sleep device giant ResMed expects to benefit from Donald Trump’s trade tariffs and tax cuts if competitors making rival products in China and Mexico are slapped with additional duties when they ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...